Paclitaxel causes de novo induction of invasive breast cancer cells by repolarizing tumor-associated macrophages

Abstract

Metastasis is the leading cause of breast cancer death, and tumor cells must migrate and invade to metastasize. Breast cancer cells that express the pro-metastatic actin regulatory protein MenaINV have an enhanced ability to migrate and intravasate within the primary tumor and extravasate at secondary sites. Though chemotherapy improves patient survival, treatment with paclitaxel leads to upregulation of MenaINV and an increase in metastasis in mice. MenaINV expression can be induced in breast cancer cells through cooperative NF-{kappa}B/ Notch1 signaling with macrophages, which are often increased in tumors in response to chemotherapy. MenaINV-expressing cells are also resistant to paclitaxel, raising the question of whether paclitaxel increases MenaINV by de novo induction or by selectively killing non-MenaINV-expressing cells. We hypothesized that paclitaxel causes de novo MenaINV induction by increasing macrophage-tumor cell NF-{kappa}B/ Notch1 signaling. Understanding this pro-metastatic effect of chemotherapy is crucial to refining treatment strategies. In this study, we demonstrate that paclitaxel increases MenaINV expression by de novo induction. Mechanistically, paclitaxel induces MenaINV by repolarizing tumor-associated macrophages towards a pro-inflammatory phenotype. These pro-inflammatory macrophages then participate in enhanced NF-{kappa}B/ Notch1 signaling with tumor cells, which leads to MenaINV induction in the tumor cells. These results lay the groundwork for novel microenvironment-based therapies to alleviate the pro-metastatic effects of chemotherapy in breast cancer.